argenx to Host Autoimmune Myositis R&D Webinar
Rhea-AI Summary
argenx (NASDAQ:ARGX) will host an R&D webinar titled “R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis” on June 23, 2026 at 2:00pm ET. The event features argenx leaders and external autoimmune myositis experts.
A live webcast and replay will be available on the argenx investor website, along with supporting presentation slides.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – ARGX
On the day this news was published, ARGX declined 5.57%, reflecting a notable negative market reaction. This price movement removed approximately $3.12B from the company's valuation, bringing the market cap to $52.81B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 03 | Clinical data update | Positive | +1.4% | New VYVGART data at EULAR 2026 showing sustained benefit and safety. |
| May 28 | R&D webinar preview | Neutral | +2.2% | Announcement of upcoming myositis-focused R&D webinar and webcast access. |
| May 27 | Investor conferences | Neutral | +1.5% | Planned participation in major June growth and healthcare conferences. |
| May 18 | Partner ecosystem news | Positive | -2.9% | MindWalk report highlighting multiple partner drug programs including argenx links. |
| May 08 | FDA label expansion | Positive | +4.0% | U.S. FDA approval expanding VYVGART use to all adult gMG serotypes. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
ARGX shares have generally reacted positively to clinical progress and event-related news, with only one recent divergence on a partner-related update.
Key Terms
fcrn medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
June 23, 2026, 7:00 AM CET
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will host a webinar titled “R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis” today, June 23, 2026, at 2:00pm ET.
argenx management and scientific leadership will be joined by external key opinion leaders:
- Avery LaChance, MD, MPH, FAAD, Associate Professor of Dermatology, Harvard Medical School; Director of Connective Tissue Disease Clinic
- Arjun Seth, MD, Assistant Professor, Neurology (Neuromuscular Disease), Northwestern University Feinberg School of Medicine
- Rohit Aggarwal, MD, MS, Professor of Medicine, University of Pittsburgh, and Co-Director of UPMC Myositis Center
Webcast Information
A live webcast of the event can be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.
Additional materials, including supporting presentation slides, will be available on argenx’s Events & Presentations website today at 2:00pm ET.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
Contacts
Media:
Colin McBean
cmcbean@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
